ATE451835T1 - Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae - Google Patents

Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae

Info

Publication number
ATE451835T1
ATE451835T1 AT00965349T AT00965349T ATE451835T1 AT E451835 T1 ATE451835 T1 AT E451835T1 AT 00965349 T AT00965349 T AT 00965349T AT 00965349 T AT00965349 T AT 00965349T AT E451835 T1 ATE451835 T1 AT E451835T1
Authority
AT
Austria
Prior art keywords
patient
compositions
viruses
protein
therapeutic methods
Prior art date
Application number
AT00965349T
Other languages
English (en)
Inventor
Stephen J Russell
Roberto Cattaneo
Kah-Whye Peng
Urs Schneider
Anthea L Murphy
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Application granted granted Critical
Publication of ATE451835T1 publication Critical patent/ATE451835T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00965349T 1999-09-24 2000-09-22 Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae ATE451835T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15587399P 1999-09-24 1999-09-24
PCT/US2000/026116 WO2001020989A1 (en) 1999-09-22 2000-09-22 Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family

Publications (1)

Publication Number Publication Date
ATE451835T1 true ATE451835T1 (de) 2010-01-15

Family

ID=22557120

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00965349T ATE451835T1 (de) 1999-09-24 2000-09-22 Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae

Country Status (6)

Country Link
EP (1) EP1217891B1 (de)
AT (1) ATE451835T1 (de)
AU (1) AU7607900A (de)
CA (1) CA2383276A1 (de)
DE (1) DE60043547D1 (de)
WO (1) WO2001020989A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241617B2 (en) 1998-07-03 2007-07-10 Dnavec Research, Inc. Sendai viral vectors comprising foreign genes inserted between the R1 and R2 Loci
CA2322057A1 (en) 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
US7402427B2 (en) 2002-04-30 2008-07-22 Dnavec Research Inc. Vectors with modified protease-dependent tropism
AU2003234342A1 (en) * 2002-05-03 2003-11-17 Mayo Foundation For Medical Education And Research Ablated slam-dependent entry
EP1369491A1 (de) 2002-06-05 2003-12-10 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
CA2802143C (en) 2003-01-14 2018-06-19 Dana-Farber Cancer Institute Sparc encoding polynucleotide as a cancer therapy sensitizer
WO2004111249A2 (en) * 2003-06-13 2004-12-23 Polymun Scientific Immunbiologische Forschung Gmbh Protein constructs containing caspase recognition sites
MXPA05013879A (es) 2003-06-18 2006-06-27 Genelux Corp Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
CA2545024A1 (en) * 2003-11-24 2005-06-02 Novo Nordisk A/S Fusion proteins and methods of cleavage of such proteins
CA2554198A1 (en) * 2004-01-22 2005-08-04 Dnavec Research Inc. Process for producing virus vector
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
KR20070085314A (ko) 2004-11-12 2007-08-27 바이엘 쉐링 파마 악티엔게젤샤프트 재조합 뉴캐슬 질환 바이러스
WO2006112930A2 (en) 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 sparc deletion mutant and uses thereof
JP5603012B2 (ja) 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
EP2415783B1 (de) 2006-10-16 2016-12-14 Genelux Corporation Modifizierte Impfstoffvirusstämme zur Verwendung in einem Diagnose- und Therapieverfahren
AU2008299020A1 (en) * 2007-09-11 2009-03-19 Sapphire Energy, Inc. Molecule production by photosynthetic organisms
EP2085092A1 (de) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Abgeschwächte onkolytische Paramyxoviren zur Kodierung von Vogel-Zytokinen
EP2085479A1 (de) * 2008-01-31 2009-08-05 Institut Pasteur Reverse Genetik von Negativstrang-RNA-Viren in Hefe
US20090208495A1 (en) * 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
EP2393921B1 (de) 2009-02-05 2015-07-15 Icahn School of Medicine at Mount Sinai Chimäres newcastle disease virus und seine verwendungen
CA2799076A1 (en) * 2010-06-10 2011-12-15 Intervet International B.V. Anti-tumor composition
KR20140128966A (ko) * 2012-01-26 2014-11-06 라이프 테크놀로지스 코포레이션 바이러스의 감염성을 증가시키는 방법
US9890361B2 (en) 2012-01-26 2018-02-13 Life Technologies Corporation Methods for increasing the infectivity of viruses utilizing alkyne-modified fatty acids
PE20151921A1 (es) 2013-03-14 2015-12-26 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle y usos de los mismos
PL3041490T3 (pl) 2013-09-03 2019-05-31 Medimmune Ltd Kompozycje zawierające atenuowany wirus choroby Newcastle i sposoby ich stosowania w leczeniu neoplazji
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
GB2583296A (en) * 2015-01-05 2020-10-21 Seagull Biosolutions Pvt Ltd Dna molecules producing custom designed replicating and non-replicating negative stranded rna viruses and uses there of
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
EP3625349B1 (de) 2017-05-16 2024-08-28 Mayo Foundation for Medical Education and Research Modifizierte viren
EP3837277A4 (de) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai Rekombinante viren der newcastle-krankheit und deren verwendungen zur prävention einer rsv-krankheit oder infektion mit dem menschlichen metapneumovirus
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
WO2025088124A1 (en) 2023-10-27 2025-05-01 Boehringer Ingelheim International Gmbh Novel assay for determining infectious virus titer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514368D0 (en) 1995-07-13 1995-09-13 Medical Res Council Improvements in or relating to binding assays
EP0780475B2 (de) * 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
US6264957B1 (en) * 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences

Also Published As

Publication number Publication date
DE60043547D1 (de) 2010-01-28
CA2383276A1 (en) 2001-03-29
EP1217891A1 (de) 2002-07-03
WO2001020989A1 (en) 2001-03-29
WO2001020989A9 (en) 2002-10-03
EP1217891B1 (de) 2009-12-16
EP1217891A4 (de) 2004-05-12
AU7607900A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
DE60043547D1 (de) Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
Sambhi et al. Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo.
Merigan et al. Purification and characterization of vertebrate interferons
ATE91630T1 (de) Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.
ATE192500T1 (de) Rekombinante viren vektoren zur expression in muskelzellen
NO20013701D0 (no) HER-2/neu-fusjonsproteiner
DE69835085D1 (de) Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor
DK1266006T3 (da) Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier
DE69829668D1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
ATE335831T1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
RU95115239A (ru) Аналог эритропоэтина
RU2001117230A (ru) Пептиды, ингибирующие трансформирующий фактор роста tgf$$$1
DK1749836T3 (da) Rekombinant vaskulær endothelcellevækstfaktor D
WO1995026411A3 (en) Composition and methods for creating syngeneic recombinant virus-producing cells
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
JP2014509197A (ja) 標的性治療人腫瘍治療の腫瘍溶解性アデノウイルス及びその応用
DE69534600D1 (de) Nukleotid- und aminosäuresequenzen der gene des hüllproteins 1 und des kernproteins von hepatitis c virus
DK11187D0 (da) Dna-sekvenser der koder for proteiner med husi-type i inhibitorers biologiske aktivitet, biotekniske fremgangsmaader til fremstilling af proteinerne o g farmaceutiske praeparater der indeholder dem
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
Hofacre et al. Efficient therapeutic protein expression using retroviral replicating vector with 2A peptide in cancer models
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
Ahmed et al. In vivo tumor suppression by adenovirus-mediated interferon alpha2b gene delivery
EP0676413A3 (de) Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung.
CN103613668A (zh) 犬、猫长效融合干扰素及其制备方法与应用
ATE229983T1 (de) Maspin- ein neues serpin mit tumor unterdrückender aktivität

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties